RabAvert Shortage: What Providers and Prescribers Need to Know in 2026

RabAvert (rabies vaccine, purified chick embryo cell; PCECV) is not currently listed on the FDA Drug Shortage database as of 2026. However, access challenges continue to affect patient care — particularly for post-exposure prophylaxis (PEP) coordination across facilities, and for patients in rural or underserved areas. This briefing summarizes the current supply landscape, clinical considerations for prescribers, and actionable tools to support patient access.

Supply Status Overview: 2026

Bavarian Nordic completed the full technology transfer for RabAvert manufacturing in October 2024, following its 2020 acquisition of Rabipur/RabAvert from GSK. Both the fill-and-finish process and bulk manufacturing are now fully operating under Bavarian Nordic. The company reported a 20% increase in Rabipur/RabAvert revenue in 2025, with U.S. market share at approximately 77%. The FDA has not issued a shortage notice or drug shortage listing for RabAvert.

Despite stable manufacturing, access difficulties persist in clinical practice because of the vaccine's specialized distribution characteristics:

• RabAvert is not routinely stocked at retail pharmacies and requires cold chain maintenance (2–8°C)
• Distribution flows through hospital, public health, and specialty pharmacy channels
• Demand is episodic and geographically unpredictable, making inventory planning difficult for individual facilities
• A per-dose cost of $393–$535 creates financial barriers to broad stocking at lower-volume sites

Interchangeability: Using Imovax When RabAvert Is Unavailable

The most clinically significant point for prescribers dealing with RabAvert access challenges is that Imovax (human diploid cell vaccine, HDCV; Sanofi Pasteur) is FDA-approved and considered interchangeable with RabAvert by ACIP. Key clinical considerations:

• Series interchangeability: ACIP states that although clinical studies of series completion with mixed products are limited, HDCV and PCECV may be used interchangeably in the same series. Most experts support switching products if needed to maintain schedule adherence.
• Egg allergy consideration: RabAvert contains ovalbumin (≤3 ng/dose) from chick embryo cell manufacturing. For patients with a history of anaphylaxis to eggs or RabAvert components, Imovax is the preferred option for PrEP. For PEP in such patients, the life-threatening nature of rabies generally means the benefit of any available vaccine outweighs allergy risk.
• Documentation: Document which product was used for each dose when mixing products across a series, and monitor for adequate antibody titer if there is any concern about response.

Clinical Protocol: Post-Exposure Prophylaxis Coordination

A challenge frequently faced by emergency medicine providers and public health officials is that the full PEP series (5 doses over 28 days for unvaccinated patients; 2 doses over 3 days for previously vaccinated) requires patients to return to a facility that stocks the vaccine multiple times. Common coordination challenges include:

• Patients who receive dose 1 in an ED and then have difficulty finding a clinic for doses 2–5
• Rural patients who must travel significant distances to facilities stocking the vaccine
• Insurance billing complexity: PEP is typically covered as a medical benefit (not a pharmacy benefit), which can create confusion when patients present to outpatient settings

Best practices for initiating PEP:

1. Ensure HRIG (20 IU/kg) is administered at the same visit as dose 1 for unvaccinated patients; infiltrate as much as anatomically feasible around the wound, with the remainder IM at a site distant from the vaccine
2. Provide patient with written documentation of dose 1 (product name, lot number, date, site of administration)
3. Proactively coordinate with the patient's PCP or an infectious disease specialist for subsequent doses before the patient leaves your facility
4. Contact the county health department if no suitable follow-up site is identified — they can often facilitate access to the remaining vaccine doses

Immunocompromised Patients: Special Considerations

Patients on immunosuppressive therapy (corticosteroids, antimalarials, chemotherapy, biologic agents, radiation therapy) may have impaired antibody responses to RabAvert. For PEP in immunocompromised patients, current CDC/ACIP guidance calls for a 5-dose series (Days 0, 3, 7, 14, and 28) regardless of prior vaccination status. Consider serologic testing 7–14 days after the final dose to confirm seroconversion.

Pre-exposure vaccination in immunocompromised patients should also include post-series serologic testing to confirm adequate response (≥0.5 IU/mL by RFFIT). Coordinate with the patient's prescribing physician to evaluate whether timing of immunosuppressive therapy can be adjusted to optimize vaccine response.

Cost and Insurance Considerations for Providers

PEP costs for uninsured patients can be substantial — $393–$535 per vaccine dose ($1,965–$2,675 for 5 doses), plus HRIG and administration. Providers can help patients navigate costs:

• Medical benefit billing: PEP is typically covered as a medical benefit under Part B (Medicare) and most private plans when medically necessary — not as a pharmacy benefit. Ensure billing is submitted correctly.
• County/state public health programs may provide PEP at reduced cost or no cost for uninsured patients
• Patient assistance is available through the legacy GSK Vaccines Access program for uninsured/low-income patients (1-866-728-4368) — direct patients to apply with provider support

Tools to Help Your Patients Find RabAvert

When patients report difficulty locating RabAvert for follow-up PEP doses or pre-exposure vaccination, direct them to medfinder for providers. medfinder calls pharmacies and clinics near the patient to identify which ones have the vaccine in stock — saving patients hours of phone calls and reducing the risk of missed doses due to access barriers.

For a comprehensive provider guide to patient access strategies, see: How to Help Your Patients Find RabAvert in Stock.